CliffBio
small molecule

CYCLOSPORINE

CYCLOSPORINE

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameCYCLOSPORINE
Active ingredientCYCLOSPORINE
Strength0.05%
Dosage formEMULSION
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalJanuary 2023
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.